United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market Insight
Published: 16 July 2026 | Report Format: Electronic (PDF) | Author: Komal and Radhika
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market is anticipated to grow at a CAGR of around 7.4% from 2025 to 2035, driven by the rising prevalence of asthma and chronic respiratory diseases
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market Forecasts to 2035
- The United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market Size was estimated at USD 0.11 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 7.4% from 2025 to 2035.
- The United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market Size is Expected to Reach around USD 0.23 Billion by 2035.
Notable Insights for the United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market
- Segmentation Based on Product Type, Portable FeNO Measuring Devices accounted for the largest market share of approximately 61.8% in 2025, supported by increasing point-of-care testing, improved portability, and growing adoption in outpatient respiratory clinics and primary healthcare settings.
- Segmentation Based on End User, Hospitals represented nearly 47.5% of market revenue in 2025, driven by increasing asthma diagnosis rates, greater use of evidence-based respiratory management, and wider implementation of FeNO testing within pulmonary and allergy departments.
- NIOX Group plc reported approximately USD 44.73 Million in revenue during fiscal 2025, supported by continued demand for FeNO monitoring systems, expansion across respiratory diagnostics, recurring consumable sales, and strengthened partnerships with healthcare providers throughout Europe.
- Medisoft Limited generated nearly USD 28.16 Million in revenue during fiscal 2025, benefiting from its advanced pulmonary diagnostic portfolio, continuous innovation in respiratory function testing, expanding hospital installations, and increasing demand for precision respiratory assessment technologies.
Download the eBook (ToC)
Research Methodologies Used to Analyze the United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market
This study combines primary and secondary research methodologies to analyze the United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market. Primary research includes interviews with respiratory physicians, pulmonologists, allergy specialists, hospital procurement managers, diagnostic device manufacturers, distributors, healthcare administrators, regulatory authorities, and industry experts. Secondary research includes company annual reports, NHS publications, scientific journals, government healthcare statistics, industry databases, and regulatory documents. Market estimates are developed using top-down and bottom-up approaches, while data triangulation ensures reliable market sizing, competitive benchmarking, and long-term forecasting accuracy.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market
- NIOX Group plc
- Medisoft Limited
- Bedfont Scientific Ltd.
- ECO PHYSICS AG
- Bosch Healthcare Solutions GmbH
- Circassia Pharmaceuticals plc
- Vyaire Medical, Inc.
- MGC Diagnostics Corporation
- Geratherm Respiratory GmbH
- CAIRE Inc.
Recent Developments:
- In October 2025, Bedfont Scientific Ltd. launched an upgraded FeNO monitoring system featuring enhanced digital connectivity, faster analysis, and improved clinical workflow to support asthma diagnosis and airway inflammation monitoring across respiratory care facilities.
- In June 2025, NIOX Group plc collaborated with a leading United Kingdom respiratory healthcare network to expand the clinical adoption of FeNO testing, supporting standardized asthma management and improving diagnostic accuracy within NHS respiratory services.
Market Segmentation
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, By Product Type
- Portable FeNO Measuring Devices
- Benchtop FeNO Measuring Device
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, By Application
- Asthma Diagnosis
- Asthma Monitoring
- Chronic Respiratory Disease Assessment
- Clinical Research
- Others
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, By End User
- Hospitals
- Specialty Respiratory Clinics
- Diagnostic Centers
- Academic & Research Institutes
- Others
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, By Distribution Channel
- Direct Sales
- Medical Device Distributors
- Online Sales
United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market, By Region
- England
- Scotland
- Wales
- Northern Ireland
Expert Views:
The United Kingdom FeNO (Fractional Exhaled Nitric Oxide) Measuring Devices Market is expected to witness steady expansion through 2035, supported by growing awareness of precision respiratory diagnostics, increasing asthma prevalence, and broader adoption of non-invasive monitoring technologies. Companies investing in portable diagnostic innovations, digital healthcare integration, and collaborative clinical initiatives are expected to strengthen their competitive position while benefiting from expanding respiratory care services and evolving NHS diagnostic pathways.
Author: Komal and Radhika By Decisions Advisors and Consulting